Emmaus Life Sciences, Inc. (EMMA): Gross Profit
$11.60M
Year ended 2025-12-31
$14.54M
Trailing 12 months to 2026-06-30
-9.8%
3-year compound annual growth
-11.1%
5-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.60M | -25.0% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $15.45M | -45.3% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $28.25M | +78.8% | 2025-04-14, From 2023-01-01 |
| 2022-12-31 | $15.80M | -8.6% | 2024-07-03, From 2022-01-01 |
| 2021-12-31 | $17.30M | -17.3% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $20.92M | -3.4% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $21.66M | +40.0% | 2021-08-10, From 2019-01-01 |
| 2018-12-31 | $15.47M | n/a | 2021-01-25, From 2018-01-01 |
| No annual figure between 2017-09-30 and 2018-12-31. | |||
| 2017-09-30 | $75.0K | n/a | 2018-12-11, From 2016-10-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $11.60M | -25.0% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $6.47M | +177.7% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $7.74M | -20.5% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $6.75M | -5.8% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $11.47M | n/a |
| uniQure N.V. (QURE) | 2025-12-31 | $14.41M | n/a |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $5.07M | -4.8% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $5.74M | -64.0% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $15.57M | +0.2% |
Compare EMMA, TNXP, JAGX, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗